OrbiMed’s Insulet PODD Stock Holding History

OrbiMed’s Portfolio PODD Stock Details PODD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-453,000	Closed	-$14M	–	139
2015 Q2	$14M	Sell	453,000 -1,544,000	-77%	-$45.5M	0.12%	94
2015 Q1	$66.6M	Hold	1,997,000	–	–	0.57%	49
2014 Q4	$92M	Buy	1,997,000 +44,000	+2%	+$1.88M	0.88%	35
2014 Q3	$72M	Hold	1,953,000	–	–	0.75%	39
2014 Q2	$77.5M	Buy	1,953,000 +19,500	+1%	+$749K	0.91%	37
2014 Q1	$91.7M	Sell	1,933,500 -955,000	-33%	-$42.2M	1.13%	28
2013 Q4	$107M	Buy	2,888,500 +36,000	+1%	+$1.33M	1.57%	22
2013 Q3	$103M	Sell	2,852,500 -196,000	-6%	-$6.58M	1.84%	19
2013 Q2	$95.8M	Buy	+3,048,500	New	+$86.4M	2.03%	18

Other funds holding PODD

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Valinor Management New York $32.2M AUM 44.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

OrbiMed's PODD Position: Q3 2015 in Review

OrbiMed sold out of Insulet (PODD) in Q3 2015, closing a stake of 453,000 shares — an estimated $14M sold.

OrbiMed first reported a position in PODD in Q2 2013 and held it in 9 quarters. The position peaked at $107M in Q4 2013. 144 funds tracked by Wall St. Rank hold PODD as of Q3 2015.

OrbiMed reported no remaining Insulet position as of Q3 2015 after selling out during the quarter.
OrbiMed sold 453,000 Insulet shares in Q3 2015, an estimated $14M.
OrbiMed first reported a position in Insulet in Q2 2013 and held it in 9 quarters.
OrbiMed's Insulet position peaked at $107M in Q4 2013.
144 funds tracked by Wall St. Rank held Insulet as of Q3 2015.

Based on OrbiMed's 13F filing for Q3 2015, filed 13 Nov 2015.